<DOC>
	<DOC>NCT00991861</DOC>
	<brief_summary>The aim of this study is to determine the efficacy, safety and tolerability of either a once or twice daily topical application of LAS41007 compared to a twice daily application of LAS106521 in the treatment of actinic keratosis.</brief_summary>
	<brief_title>Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<criteria>At least 410 clinically assessed actinic keratosis grade I to II (according to Olsen et al, 1991) in the face/forehead and/or on the bald scalp The diameter of each AK target lesion is not less than 0.5 cm and not greater than 1.5 cm The target lesions must be located in overall 2 treatment areas with a size of 25 cm2 per treatment area Have evidence of clinically significant or unstable medical conditions such as: metastatic tumor or tumor with high probability of metastatic spread heart failure (NYHA class III or higher) immunosuppressive disorder (e.g. HIV) hematologic, hepatic, renal, neurologic or endocrine disorder. collagenvascular disorder (e.g. cerebrovascular disorder or other bleedings). gastrointestinal disorder (e.g. active ulcera or history of recurrent peptic ulcera or hemorrhage) Suffer from paresthesia in the treatment areas Show Cornu cutaneum of the skin and/or hypertrophic AK lesions in the treatment areas</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Actinic Keratosis</keyword>
	<keyword>AK</keyword>
	<keyword>NMSC</keyword>
</DOC>